Search
Efonidipine
go.drugbank.com/drugs/DB09235InvestigationalThe drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001]. … Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.
Veru-111
go.drugbank.com/drugs/DB16462Investigationalin adults, and metastatic triple-negative breast cancer. … VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.
Synonyms: [2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone, Methanone, [2-(1H-indol-3-yl)-1H-imidazol-5-yl](3,4,5-trimethoxyphenyl)-Tabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigationalIt is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV). … Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs).
Lemuteporfin
go.drugbank.com/drugs/DB04980InvestigationalLemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.
TRX1
go.drugbank.com/drugs/DB05863ExperimentalTRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom. … TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells.
Calcitonin gene-related peptide
go.drugbank.com/drugs/DB06379InvestigationalIn particular, it is a potent endogenous vasodilator. … It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in the brain, gut, perivascular nerves, and other tissue.
ALGRX 1207
go.drugbank.com/drugs/DB06482ExperimentalALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted. … ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.
QS-21
go.drugbank.com/drugs/DB05400InvestigationalIt is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics. … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment